Patents by Inventor Zev Wainberg

Zev Wainberg has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Antibodies against cancer target block tumor growth, angiogenesis and metastatis
    Patent number: 9388247
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Grant
    Filed: April 3, 2009
    Date of Patent: July 12, 2016
    Assignee: The Regents of the University of California
    Inventors: Robert E. Reiter, Zev Wainberg
  • Novel Antibodies Against Cancer Target Block Tumor Growth, Angiogenesis and Metastatis
    Publication number: 20150175706
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Application
    Filed: December 16, 2014
    Publication date: June 25, 2015
    Inventors: Robert E. Reiter, Zev Wainberg
  • IDENTIFICATION OF PREDICTIVE MARKERS OF RESPONSE TO DASATINIB IN HUMAN COLON CANCER
    Publication number: 20110166154
    Abstract: Methods and compositions are provided useful in the diagnosis, treatment and management of cancers wherein cancer cells express certain polynucleotides and/or polypeptides that are differentially expressed in colon cancer subtypes that are sensitive to therapy with abl kinase inhibitors and src kinase inhibitors. In particular, PTK-7, PLK-2 and PLK-3 could be identified as markers for determining the responsiveness of cancer to dasatinib.
    Type: Application
    Filed: January 23, 2009
    Publication date: July 7, 2011
    Applicant: BRISTOL-MYERS SQUIBB COMPANY
    Inventors: Dennis J. Slamon, Richard S. Finn, Judy Dering, J. Randolph Hecht, Zev A. Wainberg, Edwin A. Clark, Charles L. Ginther
  • NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTATIS
    Publication number: 20110142838
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Application
    Filed: April 3, 2009
    Publication date: June 16, 2011
    Applicant: The Regents of the University of California
    Inventors: Robert E. Reiter, Zev Wainberg
  • NOVEL ANTIBODIES AGAINST CANCER TARGET BLOCK TUMOR GROWTH, ANGIOGENESIS AND METASTASIS
    Publication number: 20110086029
    Abstract: The present invention provides antibodies that target the first-third domains of N-cadherein and the fourth domain of N-cadherin, for diagnosis and therapy of cancers related to N-cadherein. Methods of diagnosis and treatment utilizing these antibodies are also described.
    Type: Application
    Filed: September 30, 2010
    Publication date: April 14, 2011
    Applicant: The Regents of the University of California
    Inventors: Robert E. Reiter, Zev Wainberg